Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study

Pavel ME, Dromain C, Thanh TXM, Houchard A (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Neuroendocrinology Karger

Publisher: KARGER

City/Town: BASEL

Pages Range: 157-157

Conference Proceedings Title: NEUROENDOCRINOLOGY

Authors with CRIS profile

Marianne Ellen Pavel Professur für Endokrinologie

Involved external institutions

Ipsen Pharma FR France (FR) Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV) CH Switzerland (CH)

How to cite

APA:

Pavel, M.E., Dromain, C., Thanh, T.X.M., & Houchard, A. (2019). Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study. In NEUROENDOCRINOLOGY (pp. 157-157). BASEL: KARGER.

MLA:

Pavel, Marianne Ellen, et al. "Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study." Proceedings of the NEUROENDOCRINOLOGY BASEL: KARGER, 2019. 157-157.

BibTeX: Download